Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
Open Access
- 4 March 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (6)
Abstract
The UAE implemented swift and proactive mitigation measures to combat the COVID-19 pandemic. While there are currently five primary approved vaccines in the UAE, inactivated vaccine BBIBP-CorV (Sinopharm), which has a 78% effectiveness in preventing hospitalization due to COVID-19 infections, 1 and mRNA vaccine BNT162b2 (Pfizer-BioNTech), with an effectiveness at 93% in preventing hospitalization due to COVID-19 infections, 2 are most commonly administered. Due to the successful early COVID-19 vaccination rollout, ~91.6% of the population has been vaccinated, which is mainly attributed to a model governance system, logistical capabilities, accessibility and delivery, digital infrastructure and vaccine manufacturing facility. 3Keywords
Funding Information
- Ministry of Health
- Khalifa University’s CPRA (2020-004)
This publication has 6 references indexed in Scilit:
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studyThe Lancet, 2021
- UAE efforts in promoting COVID-19 vaccination and building vaccine confidenceVaccine, 2021
- The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virusJournal of Travel Medicine, 2021
- The COVID-19 crisis and the rise of the European Centre for Disease Prevention and Control (ECDC)West European Politics, 2021
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsJAMA, 2021
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013